IPSC

Century Therapeutics Inc

IPSC.US centurytx.com
1.94
-0.09 (-4.43%)
USD · NASDAQ
52-week range
0.44
3.04
Trading at 58% of the 52-week range
Market Cap
367.58M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
1.29
Div. Yield
N/A
% Institutions
87.40%
% Insiders
8.15%

1 Year

+282.1%

3 Year

-17.8%

10 Year

-91.5%
Description

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Company Information

Company Name
Century Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US15673T1007
CIK: 0001850119
CUSIP: 15673T100
Currency: USD
Full Time Employees: 78
Phone: 267 817 5790
Fiscal Year End: December
IPO Date: Jun 18, 2021
Description:

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Address:

25 North 38th Street, Philadelphia, PA, United States, 19104

People

Directors & Officers

Name Title Year Born
Dr. Brent Pfeiffenberger M.B.A., Pharm.D. President, CEO & Chairman 1978
Dr. Gregory Russotti Ph.D. Chief Technology & Manufacturing Officer 1967
Dr. Chad A. Cowan Ph.D. Chief Scientific Officer 1972
Mr. Douglas Carr CPA Senior VP of Finance & Operations, Principal Financial Officer and Secretary NA
Krista Kauppinen J.D., Ph.D. VP, General Counsel & Head of Intellectual Property NA
Ms. Megan Bilson Chief People Officer NA
Michael Naso Ph.D. Senior VP of Cell Engineering NA
Ms. Elizabeth Devlin VP & Head of Development NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 12, 2026 Gregory Russotti N/A Sale 10.08K $2.55 $25.69K
Mar 12, 2026 Douglas Carr N/A Sale 7.04K $2.55 $17.96K
Mar 09, 2026 Gregory Russotti N/A Sale 479.00 $2.54 $1.22K
Feb 03, 2026 Douglas Carr N/A Sale 323.00 $1.82 $587.86
Dec 22, 2025 Chad Cowan N/A Purchase 58.06K $0.85 $49.35K
Dec 12, 2025 Brent Pfeiffenberger N/A Purchase 52.00K $0.58 $30.16K
Dec 08, 2025 Douglas Carr N/A Sale 257.00 $0.53 $136.21
Dec 08, 2025 Gregory Russotti N/A Sale 526.00 $0.53 $278.78
Nov 19, 2025 Brent Pfeiffenberger N/A Purchase 35.00K $0.50 $17.50K
Nov 17, 2025 Brent Pfeiffenberger N/A Sale 32.46K $0.45 $14.61K
Nov 17, 2025 Brent Pfeiffenberger N/A Sale 32.46K $0.45 $14.61K
Nov 03, 2025 Douglas Carr N/A Sale 292.00 $0.59 $172.28
Sep 08, 2025 Brent Pfeiffenberger N/A Sale 488.00 $0.50 $244.00
Sep 08, 2025 Douglas Carr N/A Sale 263.00 $0.50 $131.50
Sep 08, 2025 Gregory Russotti N/A Sale 539.00 $0.50 $269.50
Jun 09, 2025 Adrienne Farid N/A Sale 552.00 $0.62 $342.24
Jun 09, 2025 Brent Pfeiffenberger N/A Sale 475.00 $0.62 $294.50
Jun 09, 2025 Douglas Carr N/A Sale 4.90K $0.62 $3.04K
Jun 09, 2025 Gregory Russotti N/A Sale 526.00 $0.62 $326.12
May 05, 2025 Adrienne Farid N/A Sale 1.02K $0.55 $563.20

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 17.75M Mar 31, 2026 9.81% $0.43 0.00%
TCG Crossover Management, LLC 17.75M Jun 30, 2026 9.81% $1.04 0.00%
Versant Venture Management LLC 12.17M Jun 30, 2026 6.72% $18.33 0.00%
Deep Track Capital, LP 9.46M Jun 30, 2026 5.23% $0.34 -0.26%
VR Adviser, LLC 8.70M Mar 31, 2026 4.80% $0.73 0.00%
COMMODORE CAPITAL LP 8.70M Mar 31, 2026 4.80% $1.14 0.00%
RTW INVESTMENTS, LLC 8.70M Mar 31, 2026 4.80% $0.20 0.00%
Point72 Asset Management, L.P. 5.96M Mar 31, 2026 3.29% $0.02 0.05%
Vanguard Capital Management, LLC 5.69M Mar 31, 2026 3.14% $0.00 0.00%
Balyasny Asset Management LLC 5.02M Mar 31, 2026 2.77% $0.01 0.00%
Millennium Management LLC 4.19M Jun 30, 2026 2.32% $0.00 -10.12%
Trails Edge Capital Partners, LP 4.13M Jun 30, 2026 2.28% $1.61 68.77%
Spruce Street Capital LP 4.06M Jun 30, 2026 2.24% $1.95 0.00%
Adage Capital Partners Gp LLC 3.79M Jun 30, 2026 2.09% $0.01 0.00%
Woodline Partners LP 3.04M Mar 31, 2026 1.68% $0.03 0.00%
Seven Fleet Capital Management LP 2.95M Mar 31, 2026 1.63% $2.09 0.00%
Dafna Capital Management LLC 2.43M Mar 31, 2026 1.34% $1.25 -12.86%
Two Sigma Investments LLC 2.37M Mar 31, 2026 1.31% $0.00 58.53%
BlackRock Inc 1.52M Mar 31, 2026 0.84% $0.00 153.28%
DV Trading LLC 1.40M Mar 31, 2026 0.77% $0.07 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 4.34M 2.40% ▲ 0.00% Jul 31, 2026
2 iShares Russell 2000 ETF 2.98M 1.64% ▼ 0.57% Aug 31, 2026
3 Fidelity Small Cap Index 1.34M 0.74% ▲ 0.00% Jun 30, 2026
4 Vanguard Institutional Extnd Mkt Idx Tr 1.22M 0.68% ▲ 0.00% Jul 31, 2026
5 iShares Russell 2000 Value ETF 1.10M 0.60% ▼ 0.23% Aug 31, 2026
6 Russell 2000 Equity Index Fund B 799.06K 0.44% ▲ 0.00% Jun 30, 2026
7 Russell 2000 Index Non-Lendable Fund 799.06K 0.44% ▲ 0.00% Jun 30, 2026
8 Vanguard Russell 2000 ETF 690.30K 0.38% ▼ 2.52% Jul 31, 2026
9 NT Quality Small Cap Value 549.93K 0.30% ▲ 0.00% Jun 30, 2026
10 Northern Small Cap Value 549.93K 0.30% ▲ 0.00% Jun 30, 2026

Financial Highlights

Market Cap: $367.58M
EBITDA: $-95.22M
Book Value: $1.29
Earnings/Share: $-0.93
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -23.51%
ROE (TTM): -49.65%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Valuation Metrics

Enterprise Value: $294.69M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 181.08M
Shares Float: 101.36M
% Insiders: 8.15%
% Institutions: 87.40%
Short % Float: 16.34%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$109.16M
Cost of Goods Sold
adjust
$-13.10M
Gross Profit
subtotal
$96.06M
SG&A
adjust
$-24.00M
R&D
adjust
$-95.67M
Operating Income
subtotal
$-15.04M
Other / Non-Operating Items
adjust
$5.46M
Net Income
subtotal
$-9.58M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about IPSC.US!